Search
Lenvatinib
go.drugbank.com/drugs/DB09078ApprovedInvestigationalLenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that ...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesVilanterol
go.drugbank.com/drugs/DB09082ApprovedInvestigationalVilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor ...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesPinaverium
go.drugbank.com/drugs/DB09090ApprovedInvestigationalPinaverium is a spasmolytic agent used for functional gastrointestinal disorders. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function. It is shown to relieve GI spasm and pain...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDifluocortolone
go.drugbank.com/drugs/DB09095ApprovedWithdrawnDifluocortolone is a potent topical corticosteroid. It is commonly used in dermatology for the reduction of inflammation and itching. It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersSomatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawnSomatostatin, also known as growth hormone-inhibiting hormone, is a naturally-occurring peptide hormone of 14 or 28 amino acid residues that regulates the endocrine system. It is secreted by the D cells of the islets to inhibit the relea...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsDaclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnDaclatasvir is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection. It is marketed under the name DAKLINZA and is contained in daily oral tablets as the hydroch...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesMedrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawnMedrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. It was conceived as an alternative for an orally effective contraceptive option. It was developed by Ay...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSonidegib
go.drugbank.com/drugs/DB09143ApprovedInvestigationalSonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substratesp-Fluorofentanyl
go.drugbank.com/drugs/DB09177ExperimentalIllicitp-Fluorofentanyl is an opioid analgesic being an analogue of fentanyl developed by Janssen Pharmaceutica in the 1960s. p-Fluorofentanyl was sold briefly on the US black market in the early 1980s, before … introduction of the Federal Analog Act which for the first time attempted to control entire families of drugs based on their structural similarity rather than scheduling each drug individually as they appeared. p-Fluorofentanyl
Viloxazine
go.drugbank.com/drugs/DB09185ApprovedInvestigationalWithdrawnViloxazine is a selective norepinephrine reuptake inhibitor. For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. It was first approved in the UK in 1974; however, the immediate-releas...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors